Light and immune therapy combo shows promise for tough mesothelioma
NCT ID NCT04400539
First seen Nov 01, 2025 · Last updated May 04, 2026 · Updated 22 times
Summary
This study tests a new treatment for a rare and aggressive lung cancer called malignant pleural mesothelioma. The treatment combines a light-activated therapy (photodynamic therapy) given during a procedure inside the chest, followed by an immunotherapy drug (nivolumab) that helps the immune system fight cancer. The goal is to see if this combination is safe and feasible for 20 patients whose cancer has returned after standard chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT PLEURAL MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institut Coeur-Poumon, CHU
RECRUITINGLille, 59037, France
Conditions
Explore the condition pages connected to this study.